Source: South China Morning Post
Date: 22nd July 2026 

China’s limited exposure to finished generic-drug exports may reduce the immediate impact, but its role in pharmaceutical ingredients and innovative medicines keeps it central to the global industry.

The United States has announced plans to introduce substantial tariffs on imported generic medicines as part of a wider effort to encourage pharmaceutical production within the country.

Under the proposed schedule, imported generic drugs would remain tariff-free until August 2028. A 100% tariff would then apply for one year, increasing to 200% from August 2029. The long implementation period is intended to give pharmaceutical manufacturers time to establish or expand production capacity in the United States.

Although the measures could have major consequences for countries that export large volumes of finished generic medicines to the U.S., the direct impact on China may be more limited.

China’s pharmaceutical industry plays a particularly important role upstream, supplying active pharmaceutical ingredients, chemical intermediates and other materials used by drug manufacturers in several countries. Many finished generic medicines exported to the United States are therefore produced outside China but may still depend on Chinese-origin inputs.

This creates a more complex supply-chain challenge than the tariff proposal initially suggests. Moving final drug manufacturing to the United States would not necessarily eliminate dependence on internationally sourced ingredients, specialised chemicals, equipment and packaging materials.

The economics of generic medicine production may present another obstacle. Generic drugs operate under intense price competition and typically have narrower profit margins than patented medicines. Establishing production in higher-cost locations could increase manufacturing expenses, potentially placing upward pressure on medicine prices or reducing the commercial viability of certain products.

Generic medicines account for more than 90% of prescriptions dispensed in the United States, meaning any significant disruption to supply or production costs could have broad consequences for healthcare affordability and availability.

At the same time, China’s pharmaceutical sector has been expanding beyond traditional generic manufacturing and bulk pharmaceutical ingredients towards biotechnology and innovative drug development.

Cross-border licensing agreements involving innovative medicines developed in China reached approximately US$110 billion during the first half of 2026, setting a new record and demonstrating growing international demand for Chinese-developed pharmaceutical assets.

This shift means that tariffs focused primarily on finished generic medicines may not significantly slow the broader international expansion of China’s pharmaceutical industry. However, further regulatory, investment or technology restrictions could create additional complexity for global pharmaceutical partnerships.

The proposed tariffs could accelerate the restructuring of pharmaceutical manufacturing networks, particularly among companies supplying generic medicines to the United States.

Manufacturers may consider establishing U.S. production, forming local partnerships or shifting certain stages of production closer to the American market. However, developing pharmaceutical facilities requires substantial investment, regulatory approval, specialised expertise and lengthy qualification processes.

The measures could also expose the difference between relocating final manufacturing and creating a fully domestic supply chain. Even medicines produced in the United States may continue to rely on internationally sourced active ingredients and intermediate materials.

Rather than eliminating global dependencies, the tariffs may therefore redistribute them across different stages of pharmaceutical production.

The two-year transition period provides manufacturers with time to assess production footprints, investment requirements and sourcing alternatives before the first tariffs are scheduled to take effect.

However, the final impact will depend on how the policy is implemented, whether exemptions are introduced and how pharmaceutical companies respond. Industry groups have already warned that steep tariffs could increase costs and affect access to affordable medicines.

China is likely to remain influential within the global pharmaceutical ecosystem because of its upstream manufacturing capacity and expanding innovative-drug sector. Nevertheless, pharmaceutical companies may increase supplier diversification, regional production and strategic inventory holdings to reduce exposure to future trade restrictions.

What This Means

• Pharmaceutical companies should map their supply chains beyond the finished product to identify the origin of active ingredients, intermediates and critical raw materials.
• Importers should evaluate the potential effect of the proposed tariffs on landed costs, product availability and long-term supplier agreements.
• Manufacturers considering U.S. production should account for facility construction, regulatory approvals, workforce requirements and the qualification of alternative suppliers.
• Logistics providers may see changing trade flows as companies increase regional manufacturing, diversify sourcing and reposition pharmaceutical inventories.
• Businesses should continue monitoring the policy because the tariffs are not scheduled to begin until August 2028 and may be modified before implementation.

The proposed tariffs highlight the complexity of reshaping pharmaceutical supply chains. Moving final production closer to the destination market does not automatically remove reliance on globally sourced ingredients, specialised materials and technical expertise.

For pharmaceutical businesses, the priority should be to understand dependencies across every production stage rather than focusing only on the country from which the finished medicine is shipped.

Greater supplier visibility, qualified alternative sources, strategic inventory planning and temperature-controlled logistics capacity will be essential as pharmaceutical supply chains adapt. Businesses that begin scenario planning well before the proposed 2028 implementation date will be better positioned to manage cost, compliance and product-availability risks.